Efficacy and safety of tislelizumab, an anti-PD-1 antibody, versus sorafenib as first-line treatment in patients with advanced hepatocellular carcinoma in a phase 3, randomized, open-label, multicenter study - Trial in progress

Multicenter Study ◽

Study Trial ◽

Line Treatment ◽

Efficacy And Safety ◽

First Line ◽

Open Label ◽

Phase 3 ◽

A phase 3, randomized, open-label, multicenter study to compare the efficacy and safety of tislelizumab, an anti-PD-1 antibody, versus sorafenib as first-line treatment in patients with advanced hepatocellular carcinoma.

Journal of Clinical Oncology ◽

10.1200/jco.2018.36.15_suppl.tps3110 ◽

2018 ◽

Vol 36 (15_suppl) ◽

pp. TPS3110-TPS3110 ◽

Cited By ~ 8

Author(s):

Shukui Qin ◽

Richard S. Finn ◽

Masatoshi Kudo ◽

Tim Meyer ◽

Arndt Vogel ◽

...

Keyword(s):

Multicenter Study ◽

Line Treatment ◽

Efficacy And Safety ◽

First Line ◽

Open Label ◽

Phase 3 ◽

A multicenter, open-label, phase 3 trial to compare the efficacy and safety of lenvatinib (E7080) versus sorafenib in first-line treatment of subjects with unresectable hepatocellular carcinoma.

Journal of Clinical Oncology ◽

10.1200/jco.2014.32.15_suppl.tps4153 ◽

2014 ◽

Vol 32 (15_suppl) ◽

pp. TPS4153-TPS4153 ◽

Cited By ~ 8

Author(s):

Richard S. Finn ◽

Ann-Lii Cheng ◽

Kenji Ikeda ◽

Masatoshi Kudo ◽

Toshiyuki Tamai ◽

...

Keyword(s):

Line Treatment ◽

Efficacy And Safety ◽

First Line ◽

Open Label ◽

Phase 3 ◽

Unresectable Hepatocellular Carcinoma ◽

Open Label Phase ◽

Lenvatinib versus sorafenib for first-line treatment of unresectable hepatocellular carcinoma: patient-reported outcomes from a randomised, open-label, non-inferiority, phase 3 trial

The Lancet Gastroenterology & Hepatology ◽

10.1016/s2468-1253(21)00110-2 ◽

2021 ◽

Author(s):

Arndt Vogel ◽

Shukui Qin ◽

Masatoshi Kudo ◽

Yun Su ◽

Stacie Hudgens ◽

...

Keyword(s):

Patient Reported Outcomes ◽

Line Treatment ◽

First Line ◽

Open Label ◽

Phase 3 ◽

Unresectable Hepatocellular Carcinoma ◽

Carcinoma Patient ◽

Patient Reported ◽

Capecitabine and bevacizumab with or without vinorelbine in first-line treatment of HER2/neu-negative metastatic or locally advanced breast cancer: final efficacy and safety data of the randomised, open-label superiority phase 3 CARIN trial

Breast Cancer Research and Treatment ◽

10.1007/s10549-016-3727-x ◽

2016 ◽

Vol 156 (1) ◽

pp. 97-107 ◽

Cited By ~ 9

Author(s):

A. Welt ◽

N. Marschner ◽

C. Lerchenmueller ◽

T. Decker ◽

C.-C. Steffens ◽

...

Keyword(s):

Breast Cancer ◽

Locally Advanced Breast Cancer ◽

Locally Advanced ◽

Safety Data ◽

Line Treatment ◽

Efficacy And Safety ◽

First Line ◽

Open Label ◽

Phase 3 ◽

A Randomized Phase II Open-Label Multi-Institution Study of the Combination of Bevacizumab and Erlotinib Compared to Sorafenib in the First-Line Treatment of Patients with Advanced Hepatocellular Carcinoma

Oncology ◽

10.1159/000485384 ◽

2018 ◽

Vol 94 (6) ◽

pp. 329-339 ◽

Cited By ~ 7

Author(s):

Melanie B. Thomas ◽

Elizabeth Garrett-Mayer ◽

Munazza Anis ◽

Kate Anderton ◽

Tricia Bentz ◽

...

Keyword(s):

Phase Ii ◽

Line Treatment ◽

First Line ◽

Open Label ◽

Randomized Phase Ii ◽

A randomized, multicenter, phase 3 study of nivolumab vs sorafenib as first-line treatment in patients (pts) with advanced hepatocellular carcinoma (HCC): CheckMate-459.

Journal of Clinical Oncology ◽

10.1200/jco.2016.34.15_suppl.tps4147 ◽

2016 ◽

Vol 34 (15_suppl) ◽

pp. TPS4147-TPS4147 ◽

Cited By ~ 23

Author(s):

Bruno Sangro ◽

Joong-Won Park ◽

Christine Marie Dela Cruz ◽

Jeffrey Anderson ◽

Lixin Lang ◽

...

Keyword(s):

Line Treatment ◽

First Line ◽

Phase 3 ◽

Multicenter Phase ◽

Efficacy and safety of subcutaneous rituximab versus intravenous rituximab for first-line treatment of follicular lymphoma (SABRINA): a randomised, open-label, phase 3 trial

The Lancet Haematology ◽

10.1016/s2352-3026(17)30078-9 ◽

2017 ◽

Vol 4 (6) ◽

pp. e272-e282 ◽

Cited By ~ 44

Author(s):

Andrew Davies ◽

Francesco Merli ◽

Biljana Mihaljević ◽

Santiago Mercadal ◽

Noppadol Siritanaratkul ◽

...

Keyword(s):

Follicular Lymphoma ◽

Line Treatment ◽

Efficacy And Safety ◽

First Line ◽

Open Label ◽

Phase 3 ◽

Open Label Phase ◽

Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated alpha-fetoprotein (AFP) following first-line sorafenib: Pooled efficacy and safety across two global randomized Phase 3 studies (REACH-2 and REACH)

Annals of Oncology ◽

10.1093/annonc/mdy208 ◽

2018 ◽

Vol 29 ◽

pp. v122 ◽

Cited By ~ 2

Author(s):

A. Zhu ◽

R. Finn ◽

P. Galle ◽

J. Llovet ◽

J F Blanc ◽

...

Keyword(s):

Alpha Fetoprotein ◽

Line Treatment ◽

Second Line ◽

Efficacy And Safety ◽

First Line ◽

Phase 3

Faculty of 1000 evaluation for Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: interim efficacy results of the randomised, open-label, non-inferiority, phase 3 TURANDOT trial.

F1000 - Post-publication peer review of the biomedical literature ◽

10.3410/f.717976445.793471388 ◽

2013 ◽

Author(s):

Ana Maria Gonzalez-Angulo

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Metastatic Breast ◽

Line Treatment ◽

First Line ◽

Open Label ◽

Phase 3 ◽

First Line Treatment with Erlotinib Plus Bevacizumab or with Erlotinib Alone in Patients with Advanced Non-Squamous Non-Small-Cell Lung Cancer Harboring EGFR Mutations (NEJ026): An Open-Label, Randomized, Multicenter, Phase 3 Study

SSRN Electronic Journal ◽

10.2139/ssrn.3271416 ◽

2018 ◽

Author(s):

Haruhiro Saito ◽

Tatsuro Fukuhara ◽

Naoki Furuya ◽

Kana Watanabe ◽

Shunichi Sugawara ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell ◽

Egfr Mutations ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Open Label ◽

Phase 3 ◽

Multicenter Phase ◽